Jump to content
Important Survey - Please Participate ×

April, 2020: "Remimazolam: First Approval"


[La...]

Recommended Posts

"Remimazolam: First Approval"

 

https://www.ncbi.nlm.nih.gov/pubmed/32274703

 

Abstract

 

Remimazolam (Anerem® in Japan; ByFavo™ in the USA; Aptimyda™ in the EU) is an ultra-short-acting intravenous (IV) benzodiazepine sedative/anesthetic being developed by PAION AG in conjunction with a number of commercial partners for use in anesthesia and procedural sedation. Remimazolam was approved on 23 January 2020 in Japan for use in general anesthesia in adult patients. Remimazolam is also undergoing regulatory assessment in South Korea for this indication and for use in procedural sedation in the USA, the EU and China. This article summarises the major milestones in the development of remimazolam for this first approval for the induction and maintenance of general anaesthesia, and its potential upcoming approvals in general anaesthesia and procedural sedation.

Link to comment
Share on other sites

The abstract is referring only to its use for anesthesia and sedation. There's no reference to its use for any other purpose, so tapering wouldn't come into the picture.
Link to comment
Share on other sites

What's wrong with Propofol??? I had no problems with it and no withdrawal (which I'd feel because I still have anxiety). This drug I would never trust no matter what any doctors told me.
Link to comment
Share on other sites

Hi Terry,

I don't think they're looking for other options because Propofol is bad. That's not really how it works. They're always looking for more options. This benzo is obviously different in some way(s) from the other benzos that are currently available.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...